Allergan Inc. and MAP Pharmaceuticals, Inc. Announce the Federal Trade Commission Has Granted Early Termination of Waiting Period Under Hart-Scott-Rodino Act
Published: Feb 07, 2013
IRVINE, Calif. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE: AGN) (“Allergan”) and MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) (“MAP”) today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to the tender offer for all of the outstanding shares of common stock of MAP by Groundhog Acquisition, Inc. (“Purchaser”), a wholly-owned subsidiary of Allergan. As previously announced, on January 31, 2013, Purchaser initiated a tender offer to purchase all outstanding shares of common stock of MAP for $25.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes. The tender offer is being made pursuant to an Agreement and Plan of Merger, dated as of January 22, 2013, by and among Allergan, Purchaser and MAP (the “Merger Agreement”).